Chemokines in CSF of Alzheimer's disease patients

Jôice Dias Corrêa, Daniela Starling, Antônio Lúcio Teixeira, Paulo Caramelli, Tarcília Aparecida Silva

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Some studies have linked the presence of chemokines to the early stages of Alzheimer's disease (AD). Then, the identification of these mediators may contribute to diagnosis. Our objective was to evaluate the levels of beta-amyloid (BA), tau, phospho-tau (p-tau) and chemokines (CCL2, CXCL8 and CXCL10) in the cerebrospinal fluid (CSF) of patients with AD and healthy controls. The correlation of these markers with clinical parameters was also evaluated. The levels of p-tau were higher in AD compared to controls, while the tau/p-tau ratio was decreased. The expression of CCL2 was increased in AD. A positive correlation was observed between BA levels and all chemokines studied, and between CCL2 and p-tau levels. Our results suggest that levels of CCL2 in CSF are involved in the pathogenesis of AD and it may be an additional useful biomarker for monitoring disease progression.

Original languageEnglish (US)
Pages (from-to)455-459
Number of pages5
JournalArquivos de neuro-psiquiatria
Issue number3
StatePublished - Jun 2011
Externally publishedYes


  • Alzheimer's disease
  • Cerebrospinal fluid
  • Chemokines
  • Inflammation

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Biological Psychiatry


Dive into the research topics of 'Chemokines in CSF of Alzheimer's disease patients'. Together they form a unique fingerprint.

Cite this